Kick-off stakeholder network PRIME-CKD!
On Friday 24th November 2023 a diverse group of stakeholders from all over the world got together online to hear more about the PRIME-CKD consortium. Both patients, researchers and clinicians, regulatory bodies, companies and consortium partners joined the meeting chaired by Hiddo Lambers Heerspink from University Medical Center Groningen. “We all have various backgrounds and different expertise, but our goals are common: to improve the outcomes for people who suffer from chronic kidney disease” he introduced. “There are many new developments in drug development, but the implementation in clinical practice lags behind. In the PRIME-CKD consortium we want to learn how to develop biomarker-based patientprofiles that can predict the efficacy of specific drugs for specific patients.” The most common biomarkers that are used today are albuminuria and eGFR, but many more biomarkers have been identified. However, they are seldom being implemented in clinical practice. “This is a shame because they can help in giving patients a treatment tailored to their situation.”
The need for preventive and therapeutic measures are vital: around 100 million people in Europe suffer from chronic kidney disease and studies project that it will be the global 5th leading cause of death in 2040.
Hiddo presented the goals of the project, which has a duration of 5 years: “We want to unlock the full potential of these drugs. Clinicians and patients need evidence-based tools for the personalized management of CKD medication”.
The project goals for CKD patients are:
- A stakeholder network to advance implementation of biomarker-based personalized medicine approaches to clinical practice.
- A roadmap for widespread adoption and sustainability of personalized medicine and biomarker guided therapy in nephrology.
- A prototype of a clinician and patient accepted biomarker-test report that can be integrated in electronic health records and assists in clinician-patient dialogue.
The project should result in a template of how we and others can come to a successful strategy and what to do when a biomarker is identified. The stakeholder network is very important in this consortium: we want to discuss insights and requirements, barriers and solutions. Therefore, we will inform the members of the network on a regular basis, but also ask them to help us disseminate the results and exchange information.
If you have questions of want to join our growing network of stakeholders, feel free to e-mail us at primeckd@nierstichting.nl or visit our website prime-ckd.com.
